Ipsen and Medicis Announce Acceptance of Reloxin® BLA in Aesthetics by FDA

Regulatory News:
Ipsen (Paris:IPN) and Medicis (NYSE: MRX) today announced that the Food

and Drug Administration ("FDA")

has accepted the filing of Ipsen´s Biologics

License Application ("BLA")

for Reloxin®, its

botulinum toxin type A in aesthetic use (glabellar lines) in the United

States. This acceptance signifies the start of the review process of the

dossier.
In accordance with the agreement between the two parties, Medicis will

pay Ipsen approximately $25 million in connection with the announcement

made today. Subject to approval of the BLA by the FDA, Medicis will pay

to Ipsen a further $75 million and will commercialize Reloxin® in the U.S.
About Ipsen´s Botulinum Toxin Type A
As of April 2008, Ipsen´s botulinum toxin type

A, developed in the field of aesthetic medicine in the U.S., Canada and

Japan under the trademark Reloxin®

is approved for aesthetic indications in 23 countries: Argentina

Australia, Belarus, Brazil, Columbia, Ecuador, Egypt, El Salvador

Germany, Honduras, Israel, Kazakhstan, Mexico, Moldova, New Zealand

Philippines, Slovak Republic, South Korea, Ukraine, Uruguay, Venezuela

Vietnam, and Russia (in Russia, it is the first botulinum toxin type A

approved in this field). Ipsen is also pursuing regulatory approval for

medical indications for the product in certain additional key

international markets.
Dysport® is a

neuromuscular blocking toxin which acts to block acetylcholine release

hence reducing muscular spasm, and was initially developed for the

treatment of motor disorders and various forms of muscular spasticity

including cervical dystonia (a chronic condition in which the neck is

twisted or deviated), spasticity of the lower limbs (heal) in children

with cerebral palsy, blepharospasm (involuntary eye closure) and

hemifacial spasm. It was later developed for the treatment of a wide

variety of neuromuscular disorders and aesthetic medicine. Dysport® was originally launched in the United Kingdom in 1991 and has

marketing authorisations in over 70 countries (at 31 March 2008). Ipsen

has also recently filed a BLA for Dysport® in cervical dystonia to the FDA.
About Ipsen
Ipsen is a European pharmaceutical group with over 20 products on the

market and a total worldwide staff of nearly 4,000. The company´s

development strategy is based on a combination of products in targeted

therapeutic areas (oncology, endocrinology and neuromuscular disorders)

which are growth drivers, and primary care products which contribute

significantly to its research financing. This strategy is also supported

by an active policy of partnerships. The location of its four R&D

centres (Paris, Boston, Barcelona, London) gives the Group a competitive

edge in gaining access to leading university research teams and highly

qualified personnel. In 2007, Research and Development expenditure was ?185

million, in excess of 20% of consolidated sales, which amounted to ?920.5

million while total revenues amounted to ?993.8

million (in IFRS). More than 700 people in Research & Development are

dedicated to the discovery and development of innovative drugs for

patient care. Ipsen´s shares are traded on

Segment A of Eurolist by EuronextTM (stock

code: IPN, ISIN code: FR0010259150). Ipsen´s

shares are eligible to the "Service de Règlement

Différé" ("SRD") and the

Group is part of the SBF 120 index. For more information on Ipsen, visit

our website at www.ipsen.com.
Ipsen Forward-looking statements
The forward-looking statements and targets contained herein are based on

Ipsen´s management´s current views and assumptions. Such statements

involve known and unknown risks and uncertainties that may cause actual

results, performance or events to differ materially from those

anticipated herein. The Group does not commit nor gives any guarantee

that it will meet the targets mentioned above. Moreover, the Research

and Development process involves several stages at each of which there

is a substantial risk that the Group will fail to achieve its objectives

and be forced to abandon its efforts in respect of a product in which it

has invested significant sums. Therefore, the Group cannot be certain

that favorable results obtained during pre-clinical trials will be

confirmed subsequently during clinical trials, or that the results of

clinical trials will be sufficient to demonstrate the safe and effective

nature of the product concerned. Ipsen expressly disclaims any

obligation or undertaking to update or revise any forward looking

statements, targets or estimates contained in this press release to

reflect any change in events, conditions, assumptions or circumstances

on which any such statements are based, unless so required by applicable

law. The Group also faces the risk of product liability claims relating

to their safety, notably for its neuromuscular disorders products

(marketed under the brand name Dysport® notably) that may cause, or may appear to cause, serious adverse side

effects or potentially dangerous drug interactions if misused or

improperly prescribed. The Group is subject to adverse event reporting

pharmacoviligance obligations that require to report to regulatory

authorities if the Group´s products are

associated with serious adverse events, including patient death or

serious injury. These adverse events, among others, could result in

additional regulatory constraints, such as additional requests from the

regulatory authorities during reviews of applications filed for

marketing approvals in various countries which could delay the launch

time of the given products in new markets, the performance of costly

post-approval clinical studies or revisions to the approved labeling

limiting the indications or patient population for the Group´s

products or could even lead to the withdrawal of a product from the

market. Such events could harm the sales of the product and therefore

have a material negative impact on the Group´s financial situation.

Furthermore, any adverse publicity associated with such an event could

cause consumers to seek alternatives to the Group´s

products, which may cause sales to decline, even if the Ipsen product at

stake is ultimately determined not to have been the cause of the

reported serious adverse event. Ipsen´s business is subject to the risk

factors outlined in its information documents filed with the French Autorité des Marchés Financiers.
About Medicis
Medicis is the leading independent specialty pharmaceutical company in

the United States focusing primarily on the treatment of dermatological

and aesthetic conditions. The Company is dedicated to helping patients

attain a healthy and youthful appearance and self-image. Medicis has

leading branded prescription products in a number of therapeutic and

aesthetic categories. The Company´s products have earned wide acceptance

by both physicians and patients due to their clinical effectiveness

high quality and cosmetic elegance. The Company´s products include the

prescription brands RESTYLANE® (hyaluronic acid), PERLANE® (hyaluronic acid), DYNACIN® (minocycline HCl), LOPROX® (ciclopirox), PLEXION® (sodium sulfacetamide/sulfur), SOLODYN® (minocycline HCl, USP) Extended Release Tablets, TRIAZ® (benzoyl peroxide), LIDEX® (fluocinonide) Cream, 0.05%, VANOS® (fluocinonide) Cream, 0.1%, and ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL® (sodium phenylbutyrate) and AMMONUL® (sodium phenylacetate/sodium benzoate), prescription products indicated

in the treatment of Urea Cycle Disorder, and the over-the-counter brand

ESOTERICA®. For

more information about Medicis, please visit the Company´s website at www.medicis.com.
Medicis Forward-Looking Statements
This press release contains "forward-looking statements" within the

meaning of the Private Securities Litigation Reform Act. All statements

included in this press release that address activities, events or

developments that Medicis expects, believes or anticipates will or may

occur in the future are forward-looking statements, including the timing

associated with FDA´s response to the

submission and the potential commercialization of Reloxin®.

These statements are based on certain assumptions made by Medicis based

on its experience and perception of historical trends, current

conditions, expected future developments and other factors it believes

are appropriate in the circumstances. No assurances can be given

however, that these activities, events or developments will occur or

that such results will be achieved. Such statements are subject to a

number of assumptions, risks and uncertainties, many of which are beyond

the control of Medicis. Several of these risks are outlined in the

Company´s most recent annual report on Form

10-K for the year ended December 31, 2007, and other documents we file

with the Securities and Exchange Commission. Forward-looking statements

represent the judgment of Medicis´ management as of the date of this

release, and Medicis disclaims any intent or obligation to update any

forward-looking statements contained herein, which speak as of the date

hereof.
NOTE: Full prescribing information for any Medicis prescription product

is available by contacting the Company. RESTYLANE® and PERLANE® are

trademarks of HA North American Sales AB, a subsidiary of Medicis

Pharmaceutical Corporation. All other trademarks are the property of

their respective owners.